Tamoxifen discontinuance among women aged 65 years and older with estrogen receptor positive breast cancer.


648 Background: Five years ofadjuvant tamoxifen therapy in estrogen receptor (ER)-positive breast cancer is more effective than two years of use. However information on adjuvant tamoxifen therapy discontinuance is scanty. We aimed to identify predictors of tamoxifen discontinuance in older women with early stage breast cancer. METHODS Within six… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics